(AMLX) Amylyx Pharmaceuticals - Ratings and Ratios

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its lead product, RELYVRIO (sodium phenylbutyrate and tauroursodiol), is approved in the U.S. for the treatment of ALS in adults and is marketed as ALBRIOZA in Canada. The company is also advancing AMX0114, an investigational therapy targeting neurodegenerative diseases beyond ALS. Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts, and emphasizes a mission-driven approach to addressing unmet medical needs in neurodegeneration.

As of the latest data, Amylyx Pharmaceuticals, Inc. is listed under the ticker symbol AMLX on the NASDAQ exchange. The stock is classified as a common stock within the Pharmaceuticals sub-industry. The companys current resistance level is 5.2, with a support level at 2.2, indicating key price levels to watch for potential buying or selling opportunities.

From a technical standpoint, AMLX has an average 20-day volume of 711,930 shares, with a last price of 3.28. The stocks short-term trend is signaled by its SMA 20 at 3.48 and SMA 50 at 3.63, while the SMA 200 at 3.20 reflects a longer-term perspective. The ATR of 0.26 highlights moderate volatility in recent trading sessions.

Fundamentally, Amylyx has a market capitalization of $301.63 million USD. The forward P/E ratio of 2.77 suggests expectations for future earnings growth, while the P/B ratio of 1.54 indicates the stock is trading at a modest premium to its book value. The P/S ratio of 1.54 reflects the companys revenue multiple. However, the absence of a reported return on equity (RoE) may raise questions about profitability in the near term.